Table 1. Demographic and clinical characteristics.
| Monotherapy (N = 68) |
Aspirin+Clopidogrel (N = 337) |
Aspirin+Prasugrel (N = 142) |
Aspirin+Ticagrelor (N = 503) |
P-Value | |
|---|---|---|---|---|---|
| Age (years), mean (SD) | 73.3 (11.6) | 71.9 (12.9) | 61.2 (10.5) | 65.5 (12.1) | <0.001 |
| Age ≥ 75 y, n (%) | 38 (55.9) | 166 (49.3) | 15 (10.6) | 126 (25) | <0.001 |
| Gender, males, n (%) | 39 (57.4) | 236 (70) | 114 (80.3) | 374 (74.4) | 0.003 |
| BMI (Kg/m2), mean (SD) | 26.3 (4.4) | 26.8 (4.2) | 27.5 (4.2) | 27.0 (4.1) | 0.222 |
| BMI ≥ 30 Kg/m2, n (%) | 14 (20.6) | 62 (18.4) | 32 (22.5) | 102 (20.3) | 0.765 |
| Creatinine (mg/dL), median (IQR) | 1.1 (0.8–1.3) | 1.3 (0.8–1.2) | 1.0 (0.8–1.1) | 1.0 (0.8–1) | <0.001 |
| Creatinine Clerance (mL/min), mean (SD) | 68.9 (35.3) | 72.3 (37.4) | 95.7 (24.4) | 89.7 (33.4) | <0.001 |
| Creatinine Clearance: | |||||
| < 30 mL/mL | 5 (7.4) | 37 (11.0) | 1 (0.7) | 12 (2.4) | <0.001 |
| 30–59 mL/min | 25 (36.8) | 99 (29.4) | 21 (14.8) | 83 (16.5) | |
| 60–89 mL/min | 22 (32.4) | 104 (30.9) | 42 (29.6) | 167 (33.2) | |
| ≥ 90 mL/min | 16 (23.5) | 97 (28.8) | 78 (54.9) | 241 (47.9) | |
| Haemoglobin (g/dL), mean (SD) | 13.2 (1.8) | 13.1 (2.1) | 14.2 (1.5) | 13.9 (1.8) | <0.001 |
| LVEF, %, mean (SD) | 53.1 (23.7) | 49.6 (14.0) | 48.5 (11.8) | 47.9 (9.2) | 0.010 |
| LVEF<40%, n (%) | 13 (19.1) | 62 (18.4) | 15 (10.6) | 70 (13.9) | 0.090 |
| Hypertension, n (%) | 56 (82.4) | 247 (73.3) | 101 (71.1) | 357 (71) | 0.247 |
| Hypercholesterolemia, n (%) | 37 (54.4) | 184 (54.6) | 75 (52.8) | 253 (50.3) | 0.646 |
| Smoking habit, n (%) | 27 (39.7) | 121 (35.9) | 83 (58.5) | 287 (57.1) | <0.001 |
| Diabetes, n (%) | 17 (25.0) | 103 (30.6) | 38 (26.8) | 121 (24.1) | 0.215 |
| Family history for CAD, n (%) | 17 (25.0) | 79 (23.4) | 48 (33.8) | 165 (32.8) | 0.015 |
| Medical history | |||||
| Myocardial infarction, n (%) | 11 (16.2) | 81 (24) | 22 (15.5) | 85 (16.9) | 0.037 |
| PCI, n (%) | 14 (20.6) | 88 (26.1) | 18 (12.7) | 85 (16.9) | 0.001 |
| Non Valvular Atrial fibrillation | 17 (25.0) | 61 (18.1) | 4 (2.8) | 6 (1.2) | 0.001 |
| Valvular Atrial Fibrillation | 3 (4.4) | 9 (2.7) | 0 (0) | 0 (0) | 0.001 |
| Peripheral Artery Disease | 9 (13.2) | 32 (9.5) | 4 (2.8) | 29 (5.8) | 0.007 |
| Chronic Kidney Disease, n (%) | 5 (7.4) | 37 (11.0) | 1 (0.7) | 13 (2.6) | <0.001 |
| Cerebrovascular disease | 2 (2.9) | 23 (6.8) | 1 (0.7) | 7 (1.4) | <0.001 |
| Major Bleeding, n (%) | 4 (5.9) | 11 (3.3) | 0 | 5 (1) | 0.003 |
| Minor Bleeding, n (%) | 1 (1.5) | 1 (0.3) | 0 | 3 (0.6) | 0.479 |
| Admission | |||||
| Unstable Angina, n (%) | 29 (42.6) | 66 (19.6) | 3 (2.1) | 33 (6.6) | <0.001 |
| NSTEMI, n (%) | 26 (38.2) | 127 (37.7) | 25 (17.6) | 192 (38.2) | |
| STEMI, n (%) | 13 (19.1) | 144 (42.7) | 114 (80.3) | 278 (55.3) | |
| Reperfusion Strategies | |||||
| CABG, n (%) | 9 (13.2) | 9 (2.7) | 1 (0.7) | 5 (1) | <0.001 |
| PCI, n (%)) | 20 (29.4) | 267 (79.2) | 136 (95.8) | 465 (92.4) | <0.001 |
| Medical Therapy | 40 (58.8) | 66 (19.6) | 13 (9.2) | 33 (6.6) | <0.001 |
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction